| |
 |
|
Class Information
Number: 514/178
Name: Drug, bio-affecting and body treating compositions > Designated organic active ingredient containing (doai) > Cyclopentanohydrophenanthrene ring system doai > Oxygen double bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system > Oxygen single bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system
Description: Subject matter wherein one nuclear carbon of the cyclopentanohydrophenanthrene nucleus is bonded to an oxygen through a double bond and wherein another nuclear carbon atom of said cyclopentanohydrophenanthrene is bonded to at least one other oxygen through a single bond as, e.g., ether, hydroxy or alcoholate, etc.
Sub-classes under this class:
Patents under this class:
| Patent Number |
Title Of Patent |
Date Issued |
| 6194400 |
Use of amino acid precursors for the treatment of addictions |
Feb. 27, 2001 |
| 6187767 |
Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome |
Feb. 13, 2001 |
| 6187766 |
Steroid sulphatase inhibitors |
Feb. 13, 2001 |
| 6187750 |
Method of hormone treatment for patients with symptoms consistent with multiple sclerosis |
Feb. 13, 2001 |
| 6165504 |
Methods for treating hot flashes and improving the quality of life of castrated prostatic cancer patients |
Dec. 26, 2000 |
| 6166017 |
Method of using ketoconazole and related substances in medicaments for treatment of type II diabetes and methods of treating same |
Dec. 26, 2000 |
| 6159960 |
Steroid sulphatase inhibitors |
Dec. 12, 2000 |
| 6153606 |
Memory enhancement by the administration of .DELTA.5-androstene-3.beta.-ol-7,17-dione and 3.beta. esters thereof |
Nov. 28, 2000 |
| 6153607 |
Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance (or turnover) |
Nov. 28, 2000 |
| 6150348 |
Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome |
Nov. 21, 2000 |
| 6147066 |
Use of antimineralocorticoid compounds against drug withdrawal syndrome |
Nov. 14, 2000 |
| 6143736 |
Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
Nov. 7, 2000 |
| 6143738 |
Therapeutic uses for an aminosterol compound |
Nov. 7, 2000 |
| 6140315 |
Therapeutic uses of goserelin acetate |
Oct. 31, 2000 |
| 6140308 |
Colon or ileum-specific glucocorticosteroid derivatives |
Oct. 31, 2000 |
| 6140316 |
Estrene steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions |
Oct. 31, 2000 |
| 6133251 |
Combination compound for contraception based on natural estrogen |
Oct. 17, 2000 |
| 6117860 |
Steroids as neurochemical stimulators of the VNO to treat paroxistic tachycardia |
Sep. 12, 2000 |
| 6107289 |
Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-.beta. |
Aug. 22, 2000 |
| 6096733 |
Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application |
Aug. 1, 2000 |
| 6096731 |
Method for preventing tissue damage associated with graft-versus-host or host-versus-graft disease following transplantation |
Aug. 1, 2000 |
| 6093389 |
Methods and compositions for attracting and controlling termites |
Jul. 25, 2000 |
| 6090798 |
Treatment of GLC1A glaucoma with glucocorticoid antagonists |
Jul. 18, 2000 |
| 6087351 |
Method for reducing adenosine levels with a dehydroepiandrosterone and optionally a ubiquinone |
Jul. 11, 2000 |
| 6087352 |
Use of Zeranol to modulate reproductive cycles |
Jul. 11, 2000 |
| 6083941 |
Inhibition of NMDA receptor activity by pregnenolone sulfate derivatives |
Jul. 4, 2000 |
| 6083940 |
Method and composition for effecting contraception in a mammalian male |
Jul. 4, 2000 |
| 6077873 |
Steroid compounds having contraceptive and anti-osteoporosis activity |
Jun. 20, 2000 |
| 6068860 |
Pharmaceutical formulation |
May. 30, 2000 |
| 6066627 |
Steroids as neurochemical initiators of change in human blood levels of LH |
May. 23, 2000 |
| RE36701 |
Coronary heart disease treated with oestradiol |
May. 16, 2000 |
| 6048849 |
Formulations and methods of reducing toxicity of antineoplastic agents |
Apr. 11, 2000 |
| 6046184 |
Medicament for treating obesity and improving lipid metabolism |
Apr. 4, 2000 |
| 6046185 |
6,7-oxygenated steroids and uses related thereto |
Apr. 4, 2000 |
| 6046186 |
Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use |
Apr. 4, 2000 |
| 6028106 |
Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents |
Feb. 22, 2000 |
| 6028065 |
Flocculated suspension of megestrol acetate |
Feb. 22, 2000 |
| 6020327 |
Control of hair growth |
Feb. 1, 2000 |
| 6017904 |
Steroid sulphatase inhibitors |
Jan. 25, 2000 |
| 6015806 |
Antiandrogens |
Jan. 18, 2000 |
| 6013642 |
Use of estrone derivatives as steroid sulphatase inhibitors |
Jan. 11, 2000 |
| 6011026 |
Method of treating menopause or perimenopause |
Jan. 4, 2000 |
| 6011025 |
11-(substituted phenyl)-estra-4,9-diene derivatives |
Jan. 4, 2000 |
| 6011024 |
Steroid sulphatase inhibitors |
Jan. 4, 2000 |
| 5994333 |
Pregnane and cholane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods |
Nov. 30, 1999 |
| 5981517 |
Androstene derivatives |
Nov. 9, 1999 |
| 5980940 |
Pharmaceutical combination preparation for hormonal contraception |
Nov. 9, 1999 |
| 5977095 |
Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and respiratory distress syndrome |
Nov. 2, 1999 |
| 5977096 |
Steroids with radical-attracting aromatic substituents, process for the production thereof and pharmaceutical compounds containing the said substances |
Nov. 2, 1999 |
| 5972920 |
Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders |
Oct. 26, 1999 |
|
|
|
